Multiparametric MRI-based Radiomic Nomogram for Predicting HER-2 2+ Status of Breast Cancer

Overview

Journal Heliyon

Specialty Social Sciences

Date 2024 May 9

PMID 38720718

Authors

Haili Wang

Li Sang

Jingxu Xu

Chencui Huang

Zhaoqin Huang

Affiliations

Soon will be listed here.

Abstract

Objective: To explore the application of multiparametric MRI-based radiomic nomogram for assessing HER-2 2+ status of breast cancer (BC).

Methods: Patients with pathology-proven HER-2 2+ invasive BC, who underwent preoperative MRI were divided into training (72 patients, 21 HER-2-positive and 51 HER-2-negative) and validation (32 patients, 9 HER-2-positive and 23 HER-2-negative) sets by randomization. All were classified as HER-2 2+ FISH-positive (HER-2-positive) or -negative (HER-2-negative) according to IHC and FISH. The 3D VOI was drawn on MR images by two radiologists. ADC, T2WI, and DCE images were analyzed separately to extract features (n = 1906). L1 regularization, F-test, and other methods were used to reduce dimensionality. Binary radiomics prediction models using features from single or combined imaging sequences were constructed using logistic regression (LR) classifier then and validated on a validation dataset. To build a radiomics nomogram, multivariate LR analysis was conducted to identify independent indicators. An evaluation of the model's predictive efficacy was made using AUC.

Results: On the basis of combined ADC, T2WI, and DCE images, ten radiomic features were extracted following feature dimensionality reduction. There was superior diagnostic efficiency of radiomic signature using all three sequences compared to either one or two sequences (AUC for training group: 0.883; AUC for validation group: 0.816). Based on multivariate LR analysis, radiomic signature and peritumoral edema were independent predictors for identifying HER-2 2 +. In both training and validation datasets, nomograms combining peritumoral edema and radiomics signature demonstrated an effective discrimination (AUCs were respectively 0.966 and 0. 884).

Conclusion: The nomogram that incorporated peritumoral edema and multiparametric MRI-based radiomic signature can be used to effectively predict the HER-2 2+ status of BC.

References

Zhou H, Yu Y, Wang C, Zhang S, Gao Y, Pan J . A transformer-based representation-learning model with unified processing of multimodal input for clinical diagnostics. Nat Biomed Eng. 2023; 7(6):743-755. DOI: 10.1038/s41551-023-01045-x. View

Wolff A, Somerfield M, Dowsett M, Hammond M, Hayes D, McShane L . Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update. J Clin Oncol. 2023; 41(22):3867-3872. DOI: 10.1200/JCO.22.02864. View

Liu Z, Zhang X, Shi Y, Wang L, Zhu H, Tang Z . Radiomics Analysis for Evaluation of Pathological Complete Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. Clin Cancer Res. 2017; 23(23):7253-7262. DOI: 10.1158/1078-0432.CCR-17-1038. View

Dietzel M, Schulz-Wendtland R, Ellmann S, Zoubi R, Wenkel E, Hammon M . Automated volumetric radiomic analysis of breast cancer vascularization improves survival prediction in primary breast cancer. Sci Rep. 2020; 10(1):3664. PMC: 7048934. DOI: 10.1038/s41598-020-60393-9. View

Zhou J, Tan H, Li W, Liu Z, Wu Y, Bai Y . Radiomics Signatures Based on Multiparametric MRI for the Preoperative Prediction of the HER2 Status of Patients with Breast Cancer. Acad Radiol. 2020; 28(10):1352-1360. DOI: 10.1016/j.acra.2020.05.040. View

Mayerhoefer M, Materka A, Langs G, Haggstrom I, Szczypinski P, Gibbs P . Introduction to Radiomics. J Nucl Med. 2020; 61(4):488-495. PMC: 9374044. DOI: 10.2967/jnumed.118.222893. View

Mazurowski M, Zhang J, Grimm L, Yoon S, Silber J . Radiogenomic analysis of breast cancer: luminal B molecular subtype is associated with enhancement dynamics at MR imaging. Radiology. 2014; 273(2):365-72. DOI: 10.1148/radiol.14132641. View

Iima M, Honda M, Sigmund E, Kishimoto A, Kataoka M, Togashi K . Diffusion MRI of the breast: Current status and future directions. J Magn Reson Imaging. 2019; 52(1):70-90. DOI: 10.1002/jmri.26908. View

Camps-Herrero J . Diffusion-weighted imaging of the breast: current status as an imaging biomarker and future role. BJR Open. 2020; 1(1):20180049. PMC: 7592470. DOI: 10.1259/bjro.20180049. View

10.

Ha R, Jin B, Mango V, Friedlander L, Miloshev V, Malak S . Breast cancer molecular subtype as a predictor of the utility of preoperative MRI. AJR Am J Roentgenol. 2015; 204(6):1354-60. DOI: 10.2214/AJR.14.13666. View

11.

Panzironi G, Moffa G, Galati F, Marzocca F, Rizzo V, Pediconi F . Peritumoral edema as a biomarker of the aggressiveness of breast cancer: results of a retrospective study on a 3 T scanner. Breast Cancer Res Treat. 2020; 181(1):53-60. DOI: 10.1007/s10549-020-05592-8. View

12.

Zhou X, Yi Y, Liu Z, Cao W, Lai B, Sun K . Radiomics-Based Pretherapeutic Prediction of Non-response to Neoadjuvant Therapy in Locally Advanced Rectal Cancer. Ann Surg Oncol. 2019; 26(6):1676-1684. PMC: 6510882. DOI: 10.1245/s10434-019-07300-3. View

13.

Dietzel M, Baltzer P, Vag T, Groschel T, Gajda M, Camara O . Magnetic resonance mammography of invasive lobular versus ductal carcinoma: systematic comparison of 811 patients reveals high diagnostic accuracy irrespective of typing. J Comput Assist Tomogr. 2010; 34(4):587-95. DOI: 10.1097/RCT.0b013e3181db9f0e. View

14.

Nie K, Chen J, Yu H, Chu Y, Nalcioglu O, Su M . Quantitative analysis of lesion morphology and texture features for diagnostic prediction in breast MRI. Acad Radiol. 2008; 15(12):1513-25. PMC: 2791407. DOI: 10.1016/j.acra.2008.06.005. View

15.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

16.

Harada T, Uematsu T, Nakashima K, Kawabata T, Nishimura S, Takahashi K . Evaluation of Breast Edema Findings at T2-weighted Breast MRI Is Useful for Diagnosing Occult Inflammatory Breast Cancer and Can Predict Prognosis after Neoadjuvant Chemotherapy. Radiology. 2021; 299(1):53-62. DOI: 10.1148/radiol.2021202604. View

17.

Cameron D, Piccart-Gebhart M, Gelber R, Procter M, Goldhirsch A, de Azambuja E . 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017; 389(10075):1195-1205. PMC: 5465633. DOI: 10.1016/S0140-6736(16)32616-2. View

18.

Li H, Zhu Y, Burnside E, Huang E, Drukker K, Hoadley K . Quantitative MRI radiomics in the prediction of molecular classifications of breast cancer subtypes in the TCGA/TCIA data set. NPJ Breast Cancer. 2016; 2. PMC: 5108580. DOI: 10.1038/npjbcancer.2016.12. View

19.

Su M, Cheung Y, Fruehauf J, Yu H, Nalcioglu O, Mechetner E . Correlation of dynamic contrast enhancement MRI parameters with microvessel density and VEGF for assessment of angiogenesis in breast cancer. J Magn Reson Imaging. 2003; 18(4):467-77. DOI: 10.1002/jmri.10380. View

20.

Pak E, Choi K, Choi S, Park C, Kim T, Park S . Prediction of Prognosis in Glioblastoma Using Radiomics Features of Dynamic Contrast-Enhanced MRI. Korean J Radiol. 2021; 22(9):1514-1524. PMC: 8390822. DOI: 10.3348/kjr.2020.1433. View